drugset / Trial / NCT03491683
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).
Timeline
- Start
- 2018-05-31
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | INO-5401 | Other / unclassified | 3 mg | Intramuscular |
| Subject | Rocakinogene Sifuplasmid | Vaccine | 1 mg | Intramuscular |
| Background | Temozolomide | Small molecule | 75 mg/m2 | — |